23 June 2017
OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
This Interleukin-7 Antagonist (IL-7R) is developed in autoimmune diseases in a collaborative program named EFFIMab
This new milestone relates to the finalization of significant preclinical results for OSE-127 and translational data on the high expression of IL-7R in biopsies from patients with ulcerative colitis These data will be used to support the next clinical applications planned in inflammatory bowel diseases (results presented at the international congress of immunology of FOCIS – Federation of Clinical Immunology Societies * – Press release of June 15, 2017). In addition, the manufacturing process of OSE-127 is now finalized, making it possible to advance towards pilot batch production step.